Active Ingredient History
Darexaban (YM150) is a direct inhibitor of factor Xa created by Astellas Pharma. It is an experimental drug that acts as an anticoagulant and antithrombotic to prevent venous thromboembolism after a major orthopaedic surgery, stroke in patients with atrial fibrillation and possibly ischemic events in acute coronary syndrome. It is used in form of the maleate. The development of darexaban was discontinued in September 2011. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Coronary Syndrome (Phase 2)
Arthroplasty, Replacement, Hip (Phase 2/Phase 3)
Arthroplasty, Replacement, Knee (Phase 2)
Asians (Phase 1)
Atrial Fibrillation (Phase 2)
Healthy Volunteers (Phase 1)
Pharmacokinetics (Phase 1)
Thromboembolism (Phase 2)
Venous Thromboembolism (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue